Psilocybin, a psychedelic derived from mushrooms, has been proven effective as a therapy for treatment-resistant depression (TRD) in the largest study of its kind. The results of COMPASS Pathways’ Phase IIb trial have been published in The New England Journal of Medicine (NEJM). The data show that after a single 25mg dose of COMP360 psilocybin, […]
